CRISPR Gene Therapy

CRISPR gene therapy has become the definitive curative tool for genetic diseases: Vertex's Casgevy, the first FDA-approved CRISPR treatment, has cured 45 sickle cell patients in 2026, eliminating all pain crises for 18 months post-infusion. This success outpaces #5 BCI adoption by treating 500 patients across five clinical sites, with 88% achieving normal hemoglobin levels. Gene editing now targets seven additional conditions—including inherited blindness and cardiac arrhythmias—with 200 patients enrolled in trials that show 30% higher editing efficiency than the average 2023 gene therapy. Priced at $2.2 million per course, it remains costly, but early access programs have already treated 50 children at no cost, demonstrating a 70% reduction in hospitalizations compared to standard care.